THE DEAL INTELLIGENCE BRIEF · ISSUE 7 · JULY 2026
A monthly view of human capital risk and value creation for private equity, built on Deltabase culture, workforce and talent data covering 5,500+ companies and 11M employee reviews.
Editor's note
At the half-year mark, Life Sciences is one of the busiest deal markets around. PwC counted 36 pharma deals above $1bn in the first six and a half months, Altaris agreed a $600m carve-out from Clarivate, and Vertex made the largest acquisition in its history. Our data shows sentiment improving across most large pharma employers, but the gap between leaders and laggards is widening. That gap is where deal risk sits.
Lucie Odell, Deltabase
The month in three
1. Pharma M&A runs hot at the half-year
What happened: In a mid-year review published on 16 July, PwC's Roel van den Akker said there had been 36 pharma deals above $1bn in enterprise value in the first six and a half months of 2026, worth roughly $140bn in aggregate, with total M&A of about $160bn to $165bn.
The Deltabase lens: The large acquirers are mostly in better shape. Six of ten Life Sciences Top 100 companies improved their Employee NSS in 2025, led by Pfizer (up 5.6 pts to +11.6%) and Sanofi (up 4.2 pts to +21.4%).
So what: Buyers of pipeline also buy teams. An acquirer's own culture trend shapes how well it retains the scientists it pays for.
2. Altaris carves out Clarivate's life sciences unit
What happened: On 6 July, private equity firm Altaris agreed to acquire Clarivate's Life Sciences & Healthcare segment for $600m. The business provides data, analytics and technology services to pharmaceutical, biotechnology and medical device companies.
The Deltabase lens: Career Progression is the weakest point among the large pharma customers such businesses serve. In 2025 it scored −50.8% at GSK, −54.8% at Pfizer and −60.8% at Bristol Myers Squibb, with all three declining on the year.
So what: In a carve-out, employees lose the career paths of the parent. Setting out new ones before close is one of the cheapest retention levers available.
3. Vertex agrees its largest deal
What happened: Vertex agreed to acquire Crinetics Pharmaceuticals for $10bn, its biggest transaction to date, reported by Financier Worldwide on 9 July. Crinetics' once-daily acromegaly pill Palsonify was FDA-approved in September 2025, and the deal is expected to close in the third quarter.
The Deltabase lens: Culture across the sector's largest employers is diverging. The gap between the highest and lowest Employee NSS in our Life Sciences peer set widened from 13.2 pts in 2024 to 18.3 pts in 2025.
So what: As consolidation continues, the culture fit between acquirer and target matters more, not less. Diligence both sides.
Stat of the month
18.3 pts: the 2025 gap between the highest (Sanofi, +21.4%) and lowest (Bristol Myers Squibb, +3.1%) Employee NSS among ten Life Sciences Top 100 companies, up from 13.2 pts in 2024.
| Company | 2024 | 2025 | Change |
|---|
| Pfizer | +5.9% | +11.6% | +5.6 pts |
| Sanofi | +17.2% | +21.4% | +4.2 pts |
| AstraZeneca | +7.2% | +10.4% | +3.3 pts |
| Bristol Myers Squibb | +6.5% | +3.1% | −3.4 pts |
| Boehringer Ingelheim | +17.9% | +14.0% | −3.9 pts |
| GSK | +15.5% | +9.5% | −6.0 pts |
Source: Deltabase Culture data, Employee Net Sentiment Score (−100% to +100%), 2024–2025. Peer set: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Novartis, Pfizer and Sanofi.
Spotlight: Pfizer vs Bristol Myers Squibb
In 2024 the two were close, at +5.9% and +6.5%. By 2025 Pfizer had pulled ahead to +11.6% while Bristol Myers Squibb fell to +3.1%. Supportive Leadership explains much of the split: Pfizer improved 16.5 pts to −18.8%, while BMS fell 4.2 pts to −36.2%. Both lost ground on Career Progression, and BMS's Empowered score fell 7.8 pts to −62.5%. Work-Life Balance is a strength for both, at +18.5% and +29.7%. For deal teams buying assets from either, the leadership signal is the one to watch.
For your deal team
- In pipeline acquisitions, assess the acquirer's Supportive Leadership trend as well as the target's; integration runs on leadership.
- In carve-outs, define Career Progression paths before close; it is the sector's weakest culture topic.
- Use the half-year to refresh culture baselines on portfolio companies heading for exit in the second half.
Request a Human Capital due-diligence snapshot: a culture, talent and turnover read-out on any target or portfolio company. Talk to Deltabase →
Sources: Pharmaceutical Commerce (16 July 2026); The Middle Market / Mergers & Acquisitions (6 July 2026); Financier Worldwide (9 July 2026); Deltabase Culture data.